SCHEMBL17761

SCHEMBL17761

COC(=O)c1ccnc(OC)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.61
ALDH1A1 P00352 2/20 0.61
KDM6B O15054 1/20 0.60
KDM5C P41229 1/20 0.60
KDM4C Q9H3R0 1/20 0.60
KDM2A Q9Y2K7 1/20 0.60
KDM3A Q9Y4C1 1/20 0.60
ALOX15 P16050 2/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
KCNK3 O14649 1/20 0.54
KCNK9 Q9NPC2 1/20 0.54
JMJD6 Q6NYC1 1/20 0.53
HTT P42858 1/20 0.49
NPC1 O15118 1/20 0.48
HPGD P15428 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA12 O43570 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29587235 1.00 KDM4E (0.61) KDM4EALDH1A1KDM6BKDM5CKDM4C
SCHEMBL27841468 0.85 KCNK3 (0.52) KDM4EALDH1A1KDM6BKDM5CKDM4C
SCHEMBL1780507 0.84 KDM4E (0.55) KDM4EALDH1A1KDM6BKDM5CKDM4C
SCHEMBL29173821 0.84 KDM4E (0.55) KDM4EALDH1A1KDM6BKDM5CKDM4C
SCHEMBL12640026 0.83 KCNK3 (0.55) KDM4EALDH1A1KDM6BKDM5CKDM4C
SCHEMBL229446 0.83 KDM4C (0.57) KDM4EALDH1A1KDM6BKDM5CKDM4C
SCHEMBL29640109 0.83 KCNK3 (0.55) KDM4EALDH1A1KDM6BKDM5CKDM4C
SCHEMBL29556902 0.83 KDM4C (0.57) KDM4EALDH1A1KDM6BKDM5CKDM4C
SCHEMBL7456502 0.83 JMJD6 (0.55) KDM5CKDM4CKCNK3KCNK9JMJD6
SCHEMBL9944386 0.83 JMJD6 (0.55) KDM4EALDH1A1KDM6BKDM5CKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260008783-A1 MODULATORS OF FSHR AND USES THEREOF GEDEON RICHTER PLC (HU) 2026-01-08 US disclosed
EP-4577206-A2 NOVEL MODULATORS OF FSHR AND USES THEREOF Celmatix Inc. (US) 2025-07-02 EP disclosed
CN-119504731-A Naringenin derivative containing 1,3, 4-oxadiazole acylhydrazone structure and preparation method thereof 广东省科学院测试分析研究所(中国广州分析测试中心) 2025-02-25 CN disclosed
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof Ikena Oncology, Inc. (US) 2024-07-09 US disclosed
US-RE49934-E1 Inhibitors of cellular metabolic processes SERVIER PHARMACEUTICALS LLC (US) 2024-04-23 US disclosed
WO-2024044778-A2 NOVEL MODULATORS OF FSHR AND USES THEREOF CELMATIX INC. (US) 2024-02-29 WO disclosed
WO-2024044778-A2 NOVEL MODULATORS OF FSHR AND USES THEREOF CELMATIX INC. (US) 2024-02-29 WO disclosed
US-20230295147-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF ARYL THERAPEUTICS, INC. 2023-09-21 US disclosed
CN-109890822-B Inhibitors of cellular metabolic processes 安吉奥斯医药品有限公司 2022-08-30 CN disclosed
US-11325914-B1 Inhibitors of cellular metabolic processes SERVIER PHARMACEUTICALS LLC (US) 2022-05-10 US disclosed
EP-1700856-A1 THIAZOLE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-09-13 EP disclosed
EP-1250340-B1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 LILLY CO ELI (US) 2004-11-17 EP disclosed
US-20040176405-A1 Methods and compounds for inhibitting MRP1 KROIN JULIAN (US) 2004-09-09 US disclosed
US-6743794-B2 MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE ELI LILLY AND COMPANY 2004-06-01 US disclosed
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ELI LILLY AND COMPANY 2003-05-29 US disclosed
US-6509361-B1 Inhibit the activity of p38 MAP kinase. Also contemplated by the invention are processes for the preparation of the contemplated compounds and for the use of a contemplated compound in treating a mammalian host having a p38 kinase or PHARMACIA CORPORATION 2003-01-21 US disclosed
EP-1250340-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2002-10-23 EP disclosed
WO-2001046199-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2001-06-28 WO disclosed
EP-1077971-A1 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS G.D. SEARLE & CO. (US) 2001-02-28 EP disclosed
WO-1999058523-A1 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS G.D. SEARLE & CO. (US) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008783-A1 MODULATORS OF FSHR AND USES THEREOF FSHR, GNRHR, LHCGR KDM4E 1857/4885ALDH1A1 3704/4885KDM6B 3018/4885
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof AHR, ARNT, HCAR1 KDM4E 2120/4885ALDH1A1 289/4885KDM6B 1304/4885
US-20230295147-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF AHR, ARNT, HCAR1 KDM4E 2120/4885ALDH1A1 289/4885KDM6B 1304/4885
US-20040176405-A1 Methods and compounds for inhibitting MRP1 ABCC1, ABCB11, ABCB1 KDM4E 4784/4885ALDH1A1 208/4885KDM6B 4241/4885
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ABCC1, ABCB11, ABCB1 KDM4E 4752/4885ALDH1A1 264/4885KDM6B 4007/4885
US-11325914-B1 Inhibitors of cellular metabolic processes MNAT1, MAT2A, PCK2 KDM4E 1507/4885ALDH1A1 352/4885KDM6B 1004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.